<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885894</url>
  </required_header>
  <id_info>
    <org_study_id>R-1150-21</org_study_id>
    <nct_id>NCT04885894</nct_id>
  </id_info>
  <brief_title>An Examination of Cognitive Fatigue Using Functional Neuroimaging</brief_title>
  <official_title>An Examination of Cognitive Fatigue Using Functional Neuroimaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kessler Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hackensack Meridian Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Barnabas Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kessler Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to investigate the effectiveness of MS Disease&#xD;
      modifying medications on cognitive fatigue in persons with relapsing remitting multiple&#xD;
      sclerosis (RRMS). Cognitive fatigue is the kind of fatigue that occurs after intense mental&#xD;
      concentration as after a session of problem solving.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The researchers aim is to investigate the effects of disease modifying treatments on&#xD;
      cognitive fatigue and on specific brain areas that have been shown to underlie cognitive&#xD;
      fatigue in individuals with Multiple Sclerosis (MS). The researchers will investigate the&#xD;
      effects on the cognitive fatigue that develops during the performance of a demanding task,&#xD;
      and also on how cognitive fatigue changes as a function of duration of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Brain activation (BOLD signal)</measure>
    <time_frame>Measured for change at 3 time points (before, six months and 12 months after intervention)</time_frame>
    <description>A change in brain activation as measured with functional magnetic resonance imaging through blood oxygen level dependent signal will be measured in association with cognitive fatigue (as measured by the Visual Analogue scale during performance of the modified Symbol Digit Modality and Modified Fatigue Impact Scale).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue Onset</measure>
    <time_frame>Measured for change at 3 time points (before, six months and 12 months after intervention)</time_frame>
    <description>A change in the speed with which modified Symbol Digit Modality task (a cognitively demanding task) induces fatigue in MS (as measured by the Visual Analogue scale and Modified Fatigue Impact Scale).</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>MS Zeposia</arm_group_label>
    <description>Individuals with MS who will begin taking Zeposia as part of standard care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS High dose efficacy medication</arm_group_label>
    <description>Individuals with MS who will begin taking high dose efficacy oral medication as part of standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>Healthy controls, all of whom will be matched on age, education and gender to the MS groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zeposia</intervention_name>
    <description>Participants with MS will be divided into two treatment groups: those who will begin to take Zeposia, and those who plan to be begin treatment with high dose oral efficacy medication. The HC group will be free of neurological disease or injury and will be matched to the MS groups for age, gender, and education.</description>
    <arm_group_label>MS Zeposia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with Relapsing Remitting Multiple Sclerosis and Healthy Controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18-64.&#xD;
&#xD;
          -  Relapsing remitting multiple sclerosis&#xD;
&#xD;
          -  Been newly prescribed a new disease modifying medication for MS (either Zeposia or&#xD;
             other high dose oral efficacy medication)&#xD;
&#xD;
          -  or healthy volunteer who can speak English fluently.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of head injury, stroke, seizures, or any other significant neurological event&#xD;
             other than MS&#xD;
&#xD;
          -  Flare up of MS symptoms within the past month.&#xD;
&#xD;
          -  History of significant psychiatric illness (for example, bipolar disorder,&#xD;
             schizophrenia, or psychosis) or a current diagnosis of Major Depressive Disorder.&#xD;
&#xD;
          -  Pacemaker or other implanted electrical device, brain stimulator, aneurysm clip (metal&#xD;
             clips on the wall of a large artery), metallic prostheses (including metal pins and&#xD;
             rods, heart valves, and internal hearing aids [cochlear implants]), permanent&#xD;
             eyeliner, implanted delivery pumps, or shrapnel fragments.&#xD;
&#xD;
          -  left handed.&#xD;
&#xD;
          -  Not able to have an MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John DeLuca, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kessler Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy Moore</last_name>
    <phone>973-324-8450</phone>
    <email>nbmoore@kesslerfoundation.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda PraSisto</last_name>
    <phone>973-324-3507</phone>
    <email>aprasisto@kesslerfoundation.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kessler Foundation</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Amanda PraSisto</last_name>
      <phone>973-324-3507</phone>
      <email>aprasisto@kesslerfoundation.org</email>
    </contact>
    <investigator>
      <last_name>Glenn Wylie, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ekaterina Dobryakova, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helen Genova, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kessler Foundation</investigator_affiliation>
    <investigator_full_name>John DeLuca</investigator_full_name>
    <investigator_title>SVP for Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

